DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use

Colon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bow...

Full description

Bibliographic Details
Main Author: Joo Mi Yi
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/11/5/412
id doaj-d65875368cd84859a47e4a9a259b1900
record_format Article
spelling doaj-d65875368cd84859a47e4a9a259b19002021-04-30T23:04:08ZengMDPI AGLife2075-17292021-04-011141241210.3390/life11050412DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical UseJoo Mi Yi0Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, KoreaColon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bowel disease (IBD) which is characterized by chronic inflammation of the intestinal mucosa, was only partially explained by genetic studies providing susceptibility loci, but recently epigenetic studies have provided critical evidences affecting IBD pathogenesis. Over the past decade, A deep understanding of epigenetics along with technological advances have led to identifying numerous genes that are regulated by promoter DNA hypermethylation in colorectal diseases. Recent advances in our understanding of the role of DNA methylation in colorectal diseases could improve a multitude of powerful DNA methylation-based biomarkers, particularly for use as diagnosis, prognosis, and prediction for therapeutic approaches. This review focuses on the emerging potential for translational research of epigenetic alterations into clinical utility as molecular biomarkers. Moreover, this review discusses recent progress regarding the identification of unknown hypermethylated genes in colon cancers and IBD, as well as their possible role in clinical practice, which will have important clinical significance, particularly in the era of the personalized medicine.https://www.mdpi.com/2075-1729/11/5/412epigenetic regulationDNA methylationcolorectal cancerinflammatory bowel diseases (IBDs)biomarkers
collection DOAJ
language English
format Article
sources DOAJ
author Joo Mi Yi
spellingShingle Joo Mi Yi
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
Life
epigenetic regulation
DNA methylation
colorectal cancer
inflammatory bowel diseases (IBDs)
biomarkers
author_facet Joo Mi Yi
author_sort Joo Mi Yi
title DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
title_short DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
title_full DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
title_fullStr DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
title_full_unstemmed DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
title_sort dna methylation change profiling of colorectal disease: screening towards clinical use
publisher MDPI AG
series Life
issn 2075-1729
publishDate 2021-04-01
description Colon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bowel disease (IBD) which is characterized by chronic inflammation of the intestinal mucosa, was only partially explained by genetic studies providing susceptibility loci, but recently epigenetic studies have provided critical evidences affecting IBD pathogenesis. Over the past decade, A deep understanding of epigenetics along with technological advances have led to identifying numerous genes that are regulated by promoter DNA hypermethylation in colorectal diseases. Recent advances in our understanding of the role of DNA methylation in colorectal diseases could improve a multitude of powerful DNA methylation-based biomarkers, particularly for use as diagnosis, prognosis, and prediction for therapeutic approaches. This review focuses on the emerging potential for translational research of epigenetic alterations into clinical utility as molecular biomarkers. Moreover, this review discusses recent progress regarding the identification of unknown hypermethylated genes in colon cancers and IBD, as well as their possible role in clinical practice, which will have important clinical significance, particularly in the era of the personalized medicine.
topic epigenetic regulation
DNA methylation
colorectal cancer
inflammatory bowel diseases (IBDs)
biomarkers
url https://www.mdpi.com/2075-1729/11/5/412
work_keys_str_mv AT joomiyi dnamethylationchangeprofilingofcolorectaldiseasescreeningtowardsclinicaluse
_version_ 1721497210409975808